LLY

1,160.54

+2.98%↑

JNJ

231.81

+2.07%↑

ABBV

228.08

+3.32%↑

UNH

401.09

+0.74%↑

MRK

122

+2.94%↑

LLY

1,160.54

+2.98%↑

JNJ

231.81

+2.07%↑

ABBV

228.08

+3.32%↑

UNH

401.09

+0.74%↑

MRK

122

+2.94%↑

LLY

1,160.54

+2.98%↑

JNJ

231.81

+2.07%↑

ABBV

228.08

+3.32%↑

UNH

401.09

+0.74%↑

MRK

122

+2.94%↑

LLY

1,160.54

+2.98%↑

JNJ

231.81

+2.07%↑

ABBV

228.08

+3.32%↑

UNH

401.09

+0.74%↑

MRK

122

+2.94%↑

LLY

1,160.54

+2.98%↑

JNJ

231.81

+2.07%↑

ABBV

228.08

+3.32%↑

UNH

401.09

+0.74%↑

MRK

122

+2.94%↑

Home・Lista de Ações・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Fechado

SetorSaúde

185.82 3.18

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

180.22

Máximo

187.73

Indicadores-chave
By Trading Economics
Rendimento	262M -15M
Vendas	1.6M 996M
EPS	-0.3
Margem de lucro	-1.486
Funcionários	18,300
EBITDA	-11M 187M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+12.17% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	267M 8.8B
Abertura anterior	182.64
Fecho anterior	185.82

Sentimento de Notícias

By Acuity

31%

69%

77 / 344 Ranking em Healthcare

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de jun. de 2026, 21:51 UTC

Grandes Movimentos do Mercado

Merlin Shares Rally After Defense Department's Design Review Wraps

4 de jun. de 2026, 23:46 UTC

Conversa de Mercado

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 de jun. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 de jun. de 2026, 23:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 de jun. de 2026, 23:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Energy Resources of Australia to Enter Trading Halt

4 de jun. de 2026, 23:34 UTC

Conversa de Mercado

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

4 de jun. de 2026, 23:08 UTC

Conversa de Mercado

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 de jun. de 2026, 22:41 UTC

Conversa de Mercado

Australia Shares Set to Rise at the Open -- Market Talk

4 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

4 de jun. de 2026, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 de jun. de 2026, 20:16 UTC

Conversa de Mercado

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 de jun. de 2026, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 de jun. de 2026, 19:46 UTC

Conversa de Mercado

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 de jun. de 2026, 19:38 UTC

Conversa de Mercado

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 de jun. de 2026, 19:30 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 de jun. de 2026, 18:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 de jun. de 2026, 18:38 UTC

Ganhos

Money Quote: Tech Weakness in Context -- WSJ

4 de jun. de 2026, 18:24 UTC

Ganhos

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 de jun. de 2026, 17:09 UTC

Conversa de Mercado

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 de jun. de 2026, 16:58 UTC

Ganhos

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 de jun. de 2026, 16:46 UTC

Conversa de Mercado

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 de jun. de 2026, 16:38 UTC

Ganhos

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

4 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

4 de jun. de 2026, 16:13 UTC

Conversa de Mercado

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 de jun. de 2026, 16:11 UTC

Conversa de Mercado

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 de jun. de 2026, 15:56 UTC

Conversa de Mercado

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

12.17% parte superior

Previsão para 12 meses

Média 208.4 USD 12.17%

Máximo 235 USD

Mínimo 160 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

77 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.